Taspoglutide (RO5073031)on cardiovascular outcomes in Type 2 diabetes

• Research type

  Research Study

• Full title

  A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in patients with inadequately controlled type 2 diabetes and established cardiovascular disease

• IRAS ID

  34331

• Sponsor organisation

  F. Hoffmann-La Roche Ltd

• Eudract number

  2009-014986-22

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  N/A

• REC name

  East of England - Cambridge East Research Ethics Committee

• REC reference

  09/H0304/80

• Date of REC Opinion

  5 Jan 2010

• REC opinion

  Further Information Favourable Opinion